Premium
Betaxolol: A New Long‐Acting Beta 1 ‐Selective Adrenergic Blocker
Author(s) -
Frishman William H.,
Tepper David,
Lazar Eliot J.,
Behrman Douglas
Publication year - 1990
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1990.tb03627.x
Subject(s) - betaxolol , bioavailability , pharmacology , pharmacokinetics , agonist , adrenergic agonist , medicine , partial agonist , anesthesia , receptor , timolol , surgery , intraocular pressure
Betaxolol (Searle, Skokie, Illinois) is a new beta 1 ‐selective adrenergic blocker with no partial agonist action and minimal membrane stabilizing activity. Its pharmacokinetic profile is characterized by a long serum half‐life and excellent oral bioavailability, with little first‐pass metabolism. The mean 16‐hour half‐life of betaxolol has been shown to provide full 24‐hour control of blood pressure and heart rate. Betaxolol has been proven to be a safe and effective antihypertensive agent, and was recently approved for clinical use in the United States for this indication.